Research projects

BEACON Immuno (anti-GD2 amendment)

The BEACON study is a chemotherapy and antibody combination trial. Read more

National Neuroblastoma Genetics Reference Centre

The National Neuroblastoma Genetics Reference Centre aims to provide a comprehensive service genetic characterisation of all neuroblastoma tumours at diagnosis and a subset at relapse. Read more

PTPP – ITCC-P4 Collaboration

Bringing together American NCI PPTC and European ITCC-P4 paediatric preclinical research consortiums together for the first time ever via the Pediatric Cancer Working Group at the AACR Annual Meeting. Read more

MiNivAn : Phase I study of I-131 MIBG, nivolumab and ch14.18/CHO

MiNivAn aims to improve the cure rate of children with relapsed or refractory neuroblastoma by combining targeted radiotherapy (I-131 MIBG) with the antibodies anti-GD2 (ch14.18/CHO) and anti-PD1 (nivolumab). Read more

Biomarker evaluation of neuroblastoma mRNAs in children enrolled in the BEACON trial

In this study, blood and bone marrow samples from 120 children treated in the BEACON-Neuroblastoma trial will be collected in order to analyse levels of neuroblastoma mRNAs Read more

Lorlatinib (PF-06463922) : Third-generation ALK inhibitor

This exciting new clinical trial sees 17 transatlantic centres in the UK, USA and Europe, recruiting patients simultaneously for an innovative new third-generation ALK-inhibitor agent lorlatinib (PF-06463922). Read more

Neuroblastoma Senior Trials Coordinator

Solving Kids’ Cancer funds a dedicated Senior Trials Coordinator for Neuroblastoma within the Children’s Cancer Trials Team (CCTU) of the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham. Read more

Grant awarded to open SIOPEN High-Risk Neuroblastoma Clinical Trial 2 across the UK in 2021

Grant Award - High-Risk Neuroblastoma Clinical Trial 2 Read more

Charities fund new clinical trial

Solving Kids’ Cancer, with Neuroblastoma UK, has awarded a grant of £609,762.40 to enable the SIOPEN High-Risk Neuroblastoma Clinical Trial 2 (HR-NBL2) to open in the UK, it is anticipated to open in early 2021. Read more

Grant awarded to identify markers of poor survival in high-risk neuroblastoma

Solving Kids’ Cancer Europe, Solving Kids' Cancer in New York, Oscar Knox Fund and Merryn Lacy Trust have awarded a grant of $420,000 to co-investigators. Read more

Grant awarded to identify markers of poor survival in high-risk neuroblastoma

Solving Kids’ Cancer Europe, Solving Kids' Cancer in New York, Oscar Knox Fund and Merryn Lacy Trust have awarded a grant of $420,000 to co-investigators. Read more

Landmark Transatlantic Trial for Children with High-Risk Neuroblastoma Funded by Parent-Led Charities

In a landmark in paediatric oncology research, children with high-risk neuroblastoma across Europe and North America will be treated together for the first time. Read more

Grant Awarded for Research into Identifying and Treating Chemotherapy-Resistant Neuroblastoma

Solving Kids’ Cancer UK with partners; Solving Kids’ Cancer in New York, Joining Against Cancer in Kids (J-A-C-K), ZOE4LIFE, Merryn Lacy Trust and the Oscar Knox Fund have awarded £500,000 to the Children’s Hospital of Philadelphia (CHOP) and collaborating institutions for research into identifying and treating neuroblastoma in newly diagnosed children that is resistant to current standard chemotherapy. Read more

International Neuroblastoma Research Initiative 2018

Solving Kids’ Cancer is leading an international competitive funding call commencing with a Request for Applications (RFA) Read more

International Research Initiative 2019

Solving Kids’ Cancer has issued a joint 2019 International Challenge Grant Call for GBP 500,000 awarded over three years Read more

Latest

Cross-party MPs back calls for a UK-led vaccine trial to help children with cancer
Cycle SWFC to MK Dons

Jude’s dad, Arron, made his SWFC debut in a win against MK Dons. So it feels very fitting that this should be the match of choice for a cycling challenge - the team will begin at SWFC ground and finish at MK Dons stadium.
Kathryn's RSR for Jude

To help Jude's family reach their fundraising target.
St Mary Magdalene - Y5 and Y6 Ticket Sales

Beau's Campaign

Beau was diagnosed with high-risk neuroblastoma, an aggressive childhood cancer that has a 40-50% chance of long-term survival at diagnosis, in December 2020. Her family are appealing for your help to raise £317,000 by May 2022.
Flora's Campaign

In January 2021 Flora was diagnosed with Autism Spectrum Disorder, and just three months later her parents were given the devastating news she had high-risk neuroblastoma. Her family are appealing for your help to raise £252,000 by August 2022 for Flora to enrol on the Bivalent Vaccine clinical trial in New York that aims to stop her neuroblastoma from coming back.
Joseph Yeandle

We are devastated to share the news that beautiful Joseph has sadly passed away.
Jude's Campaign

Jude is a Dinosaur and animal-loving three-year-old. In July 2021 Jude was diagnosed with high-risk neuroblastoma, a rare and aggressive childhood cancer that has a 40-50% chance of long-term survival at diagnosis.
Maysaa's Campaign

Four-year-old Maysaa was diagnosed with high-risk neuroblastoma, an aggressive childhood cancer that has a 40-50% chance of long-term survival at diagnosis, in March 2021. Her family are asking for your support to raise £106,000 by August 2022 for Maysaa to enrol on the DFMO study in Charlotte that aims to stop her neuroblastoma from coming back.
Chloe’s Journey

Beautiful Chloe passed away on the 4th of February 2022.
Eden's Campaign

Six-year-old Eden was diagnosed with high-risk neuroblastoma, an aggressive childhood cancer that has a 40-50% chance of long-term survival at diagnosis, in April 2021.
Kayla's Campaign

Three-year-old Kayla was diagnosed with high-risk neuroblastoma in May 2021. Kayla’s parents are asking for your help to raise £221,000 by November 2022 for Kayla to enrol on the bivalent vaccine clinical trial in New York that aims to stop her neuroblastoma from coming back.
Peter's Campaign

11-year-old Peter was diagnosed with neuroblastoma in early 2019. Devastatingly he relapsed in August 2020 after being clear of disease for 6 months. Thanks to your incredible fundraising and support, Peter was able to enrol on the DFMO study in Charlotte at the end of January 2022.
Dulcie's Campaign

In December 2021, five-year-old Dulcie was diagnosed with high-risk neuroblastoma, a rare and aggressive childhood cancer that has a 40-50% chance of long-term survival at diagnosis.